Simple record

dc.rights.licenseAttribution 4.0 International*
dc.contributor.authorSoto-Gordoa, Myriam
dc.contributor.otherMar Medina, Javier
dc.contributor.otherGorostiza, Ania
dc.contributor.otherIbarrondo Olagüenaga, Oliver
dc.contributor.otherArrospide, Arantzazu
dc.contributor.otherMartinez-Lage, Pablo
dc.description.abstractBackground: The LipiDiDiet trial showed that Souvenaid, a medical food, might delay progression to dementia in prodromal Alzheimer’s disease (AD). The objective of this study was to assess the cost-utility of Souvenaid compared to placebo in patients with prodromal AD under the conditions applied in that trial. Methods: A discrete event simulation model was developed based on the LipiDiDiet trial and a literature review to assess the cost-utility of Souvenaid from a societal perspective considering direct and indirect costs. For both intervention and control groups, patient trajectories in terms of functional decline on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale in LipiDiDiet were reproduced statistically with mixed models by assigning time until events to simulated patients. From the societal perspective, four scenarios were analysed by combining different options for treatment duration and diagnostic test cost. Univariate sensitivity analysis assessed parameter uncertainties. Results: Validation results at year 2 of disease progression fit with CDR-SB progression in LipiDiDiet. The incremental cost-utility ratio (ICUR) in the baseline case was €22,743/quality-adjusted life year (QALY). All scenarios rendered an ICUR lower than €25,000/QALY (the societal threshold). Moreover, the treatment option was costsaving and increased health benefits when diagnostic costs were not considered and treatment was only administered during the prodromal stage. Conclusions: Treating prodromal AD with Souvenaid is a cost-effective intervention in all scenarios analysed. The LipiDiDiet trial showed a modest improvement in disease course but as the social costs of AD are very high, the intervention was efficient. Assessing small benefits at specific stages of AD is relevant because it is reasonable to expect that no effective, safe and affordable disease-modifying therapies will become available in the short to medium term.en
dc.publisherBioMed Central Ltd. Part of Springer Natureen
dc.rights© The Author(s). 2020en
dc.subjectProdromal Alzheimer’s diseaseen
dc.subjectClinical dementia ratingen
dc.titleEconomic evaluation of supplementing the diet with 1 Souvenaid in patients with prodromal Alzheimer's diseaseen
dcterms.sourceAlzheimer's Research and Therapyen
local.contributor.groupInnovación, gestión, organización
local.rights.publicationfeeamount2570 EURen
local.source.detailsVol. 12. N. Articulo 166, 2020en

Files in this item


This item appears in the following Collection(s)

Simple record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International